GMAB Company Profile and Key Details
Genmab A/S
GMAB Stock Price Chart
Stock Price Today
Genmab A/S (GMAB) stock surged +0.52%, trading at $19.21 on NASDAQ, up from the previous close of $19.11. The stock opened at $19.19, fluctuating between $19.13 and $19.43 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Company Information
| Employees | 2635 |
| Beta | 0.86 |
| Sales or Revenue | $16.47B |
| 5Y Sales Change% | 49.614% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Genmab A/S (NASDAQ: GMAB) stock price is $19.21 in the last trading session. During the trading session, GMAB stock reached the peak price of $19.43 while $19.13 was the lowest point it dropped to. The percentage change in GMAB stock occurred in the recent session was 0.52% while the dollar amount for the price change in GMAB stock was $0.10.
The NASDAQ listed GMAB is part of Biotechnology industry that operates in the broader Healthcare sector. Genmab A/S designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
No Data
GMAB's closing price is 1.1% higher than its 52-week low of $19.00 where as its distance from 52-week high of $31.88 is -39.74%.
Number of GMAB employees currently stands at 2,635.
Official Website of GMAB is: https://www.genmab.com
GMAB could be contacted at phone 457 020 2728 and can also be accessed through its website. GMAB operates from Kalvebod Brygge 43, Copenhagen, 1560, Denmark.
GMAB stock volume for the day was 1.06M shares. The average number of GMAB shares traded daily for last 3 months was 1.38M.
The market value of GMAB currently stands at $12.20B with its latest stock price at $19.21 and 635.24M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com